Acute Lymphoblastic Leukemia in Children: Recent Findings
ALL is the most common cancer in children and is among the most curable of the pediatric malignancies. Many clinical, biological, genetic, and molecular features have been identified as having prognostic significance in the outcome of patients with ALL. Prognostic features play a critical role in directing therapy for ALL and as scientific and treatment advances are made, this area of investigation changes rapidly. This session will discuss the importance of prognostic factors that may influence the treatments used for patients with ALL, as well as review treatment protocols designed to reduce toxicity while preserving efficacy for ALL patients.
Learning Objectives
At the end of this educational activity, participants should be able to
- Identify prognostic factors that influence treatment and outcomes for patients with ALL
- Discuss treatment protocols designed to reduce toxicity while preserving efficacy for patients with ALL
Faculty Listing
Nobuko Hijiya, MD
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine;
Hematology, Oncology and Stem Cell Transplant
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
Disclosures of Relevant Financial Relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or their spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control.
OptumHealth Education ensures that the content is independent of commercial bias.
Financial Relationship Key A-Advisory Board C-Consultant E-Employee G- Grant/Research Support I-Stocks and Other Ownership Interests S-Speakers’ Bureau O-Other Financial or Material Support N-Nothing to disclose X-Will disclose onsite | Resolution Key R1-Restricted to Best Available Evidence R2-Removed/Altered Financial Relationship R3-Refrain from Recommending Products or Services R4-Peer Review of Presentation R5-Ensure that content is independent of commercial bias R6-Recommend an alternative speaker for this topic for the planning committee’s consideration N/A-Not Applicable |
Last Name | First Name | Disclosure | Resolution | Role |
Abecassis | Michael | N | N/A | Planner |
Chart-Hart | Sarah | UnitedHealth Group (E) (I) | R5 | Planner |
Gleason | Rebecca | UnitedHealth Group (E) (I) | R5 | Planner |
LeMaistre | C. Fred | N | N/A | Planner |
Mulligan | David C. | N | N/A | Planner |
Roberts | John P. | Gilead (C) | R5 | Planner |
Rome | Arlene | UnitedHealth Group (E) (I) | R5 | Planner |
Sendaydiego | Anne M. | N | N/A | Planner |
Hijiya | Nobuko | Pfizer, Sigma Tau (A); Jazz Pharma (C); Sanofi (C) (O) | R1, R3 | Faculty |
Method of Participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Participants will receive a certificate upon successful completion of the activity, which includes the following:
- Completing the entire activity
- Completing the Pre- and Post-Activity Assessments, Activity Evaluation, and Application for Certificate of Credit forms
You must be logged into your account to participate in this activity. Get started by clicking “Begin” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save, or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under “My Account”, “My Activities.”
Method for Calculating CE Credit
CE credit was calculated by the complexity of content.
Provided By
This activity is provided by OptumHealth Education.
Commercial Support
This activity is supported by an educational grant from Onyx Pharmaceuticals.
Hardware/Software Requirements
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software prior to the beginning of this activity.
Target Audience
This activity is designed to meet the educational needs of physicians, nurses, pharmacists, case managers, and other health care professionals.
Available Credit
- 0.75 ACPE - Pharmacists
- 0.75 AMA - Physicians
- 0.75 ANCC - Nurses
- 0.75 Attendance - General Attendance
- 0.75 CCMC - General - Case Managers